Identifying <font color="blue">patients_4</font> <font color="blue">at_4</font> <font color="blue">high_4</font> <font color="blue">risk_4</font> <font color="blue">for_4</font> <font color="blue">neutropenic_4</font> <font color="blue">complications_4</font> <font color="blue">during_2</font> <font color="blue">chemotherapy_2</font> <font color="blue">for_2</font> <font color="blue">metastatic_2</font> <font color="blue">breast_2</font> <font color="blue">cancer_2</font> <font color="blue">with_1</font> <font color="blue">doxorubicin_1</font> <font color="blue">or_1</font> <font color="blue">pegylated_1</font> <font color="blue">liposomal_1</font> <font color="blue">doxorubicin_1</font> <font color="blue">:_1</font> the development of a prediction model . 
<br>
<br> OBJECTIVE <font color="blue">To_1</font> <font color="blue">develop_1</font> <font color="blue">a_1</font> <font color="blue">cycle_1</font> <font color="blue">-_1</font> <font color="blue">based_1</font> <font color="blue">risk_1</font> <font color="blue">prediction_1</font> <font color="blue">model_1</font> <font color="blue">for_1</font> <font color="blue">neutropenic_1</font> <font color="blue">complications_1</font> <font color="blue">(_1</font> <font color="blue">NC_1</font> <font color="blue">)_1</font> <font color="blue">during_1</font> <font color="blue">chemotherapy_1</font> <font color="blue">with_1</font> <font color="blue">doxorubicin_1</font> <font color="blue">(_1</font> <font color="blue">DOX_1</font> <font color="blue">)_1</font> <font color="blue">or_1</font> <font color="blue">a_1</font> <font color="blue">pegylated_1</font> <font color="blue">liposomal_1</font> <font color="blue">formulation_1</font> <font color="blue">(_1</font> <font color="blue">PLD_1</font> <font color="blue">)_1</font> <font color="blue">for_1</font> <font color="blue">patients_5</font> <font color="blue">with_5</font> <font color="blue">metastatic_5</font> <font color="blue">breast_5</font> <font color="blue">cancer_5</font> <font color="blue">(_5</font> <font color="blue">MBC_5</font> <font color="blue">)_5</font> <font color="blue">._4</font> <font color="blue">
<br>_1</font> <font color="blue">METHODS_1</font> <font color="blue">Data_1</font> <font color="blue">analyzed_1</font> <font color="blue">was_1</font> <font color="blue">from_1</font> <font color="blue">a_1</font> <font color="blue">phase_1</font> <font color="blue">III_1</font> <font color="blue">,_1</font> <font color="blue">randomized_1</font> <font color="blue">clinical_1</font> <font color="blue">trial_1</font> <font color="blue">of_1</font> <font color="blue">DOX_1</font> <font color="blue">(_1</font> <font color="blue">60_1</font> <font color="blue">mg_1</font> <font color="blue">/_1</font> <font color="blue">m(2_1</font> <font color="blue">)_1</font> <font color="blue">every_1</font> <font color="blue">3_1</font> <font color="blue">weeks_1</font> <font color="blue">)_1</font> <font color="blue">or_1</font> <font color="blue">PLD_1</font> <font color="blue">(_1</font> <font color="blue">50_1</font> <font color="blue">mg_1</font> <font color="blue">/_1</font> <font color="blue">m(2_1</font> <font color="blue">)_1</font> <font color="blue">every_1</font> <font color="blue">4_1</font> <font color="blue">weeks_1</font> <font color="blue">)_1</font> <font color="blue">for_1</font> <font color="blue">the_1</font> <font color="blue">first_1</font> <font color="blue">line_1</font> <font color="blue">therapy_1</font> <font color="blue">for_1</font> <font color="blue">MBC_1</font> <font color="blue">(_1</font> <font color="blue">n_2</font> <font color="blue">=_2</font> <font color="blue">509_2</font> <font color="blue">)_2</font> <font color="blue">(_1</font> <font color="blue">O'Brien_1</font> <font color="blue">et_1</font> <font color="blue">al_1</font> <font color="blue">,_1</font> <font color="blue">Ann_1</font> <font color="blue">Oncol_1</font> <font color="blue">._1</font> <font color="blue">2004;15:440_1</font> <font color="blue">-_1</font> <font color="blue">449_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> <font color="blue">NC_1</font> <font color="blue">were_1</font> <font color="blue">defined_1</font> <font color="blue">as_1</font> <font color="blue">an_1</font> <font color="blue">absolute_1</font> <font color="blue">neutrophil_1</font> <font color="blue">count_1</font> <font color="blue"><_1</font> <font color="blue">or_1</font> <font color="blue">=_1</font> <font color="blue">1.5_1</font> <font color="blue">x_1</font> <font color="blue">10(9_1</font> <font color="blue">)_1</font> <font color="blue">cells_1</font> <font color="blue">/_1</font> <font color="blue">L_1</font> <font color="blue">(_1</font> <font color="blue">ie_1</font> <font color="blue">,_1</font> <font color="blue">>_1</font> <font color="blue">or_1</font> <font color="blue">=_1</font> <font color="blue">grade_1</font> <font color="blue">II_1</font> <font color="blue">)_1</font> <font color="blue">before_1</font> <font color="blue">the_1</font> <font color="blue">next_1</font> <font color="blue">cycle_1</font> <font color="blue">,_1</font> <font color="blue">febrile_1</font> <font color="blue">neutropenia_1</font> <font color="blue">or_1</font> <font color="blue">neutropenia_1</font> <font color="blue">with_1</font> <font color="blue">a_1</font> <font color="blue">documented_1</font> <font color="blue">infection_1</font> <font color="blue">._1</font> <font color="blue">Patient_2</font> <font color="blue">and_1</font> <font color="blue">hematologic_1</font> <font color="blue">factors_1</font> <font color="blue">potentially_1</font> <font color="blue">associated_1</font> <font color="blue">with_1</font> <font color="blue">NC_1</font> <font color="blue">were_1</font> <font color="blue">evaluated_1</font> <font color="blue">._1</font> Factors with a P value of < or = 0.25 within a cycle were included in a generalized estimating equations regression model . Using backward elimination , we derived a risk scoring algorithm ( range 0 - 63 ) from the final reduced model . 
<br> RESULTS Risk factors retained in the model included poor performance status , absolute neutrophil count < or = 2.0 x 10(9 ) cells / L in the previous cycle , the first cycle of chemotherapy , DOX versus PLD and advanced age . A precycle risk score from > or = 25 to < 40 for a given <font color="blue">patient_1</font> was identified as being the optimal threshold for sensitivity ( 58.0% ) and specificity ( 78.7% ) . <font color="blue">Patients_1</font> with a score at or beyond this threshold would be considered at high risk for developing NC in later cycles . 
<br> CONCLUSION The use of this model may enhance <font color="blue">patient_1</font> care by targeting preventative therapies ( eg , granulocyte colony stimulating factor or PLD ) to those <font color="blue">MBC_1</font> <font color="blue">patients_2</font> most likely to experience NC during anthracycline - based chemotherapy .